Skip to main content
SpringerLink
Log in

Virushepatitis B und C

Viral Hepatitis B und C

  • UPDATE
  • Published:
Medizinische Klinik Aims and scope Submit manuscript

Zusammenfassung

Die chronischen Virushepatitiden B und C können zu Leberzirrhose, Leberzellkarzinom und Tod führen. Die Behandlung dieser weltweit häufigen Infektionskrankheiten unterliegt einer raschen Entwicklung mit Etablierung neuer antiviraler Substanzen und Verbesserung der Therapiestrategien anhand molekularvirologischer Parameter. Therapieziel ist die Kontrolle bzw. Elimination der Virusinfektion und damit Verhinderung von Hepatitis-B- und -C-assoziierten Komplikationen. Während Interferon alfa in der Behandlung der Hepatitis B heute seltener eingesetzt wird, stellen die lang wirksamen pegylierten und albumingekoppelten Interferone weiterhin einen wichtigen Bestandteil der Hepatitis-C-Therapie dar. Die wachsende Zahl „gezielter Therapien“ in Form neuer Nukleos(t)id-Analoga, HCV-Protease-, RNA-Polymerase-Inhibitoren und anderer Virustatika hat auch zu einer Zunahme der Komplexität in der Behandlung der Virushepatitis geführt. Dieses Update fasst den aktuellen Stand und neue Entwicklungen in der Therapie der chronischen Virushepatitis B und C zusammen.

Abstract

Chronic hepatitis B (HBV) and C virus (HCV) infection can lead to liver cirrhosis, hepatocellular carcinoma and death. Treatment of these worldwide prevalent infectious diseases is subject to intensive research efforts with development of new antiviral substances and optimization of treatment strategies using molecular markers. The goal of HBV and HCV treatment is control and elimination of viral replication, respectively, thereby preventing hepatitisassociated complications. While interferon alfa is used less frequently to treat hepatitis B today, it is still (in the pegylated or albumin-fused form) an essential component of hepatitis C therapy. The growing number of targeted therapies such as new nucleos(t)ide analogs, HCV protease and RNA polymerase inhibitors and other new compounds has added complexity to the treatment of viral hepatitis. This update summarizes the current standard of care as well as new developments in chronic hepatitis B and C therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. RKI. Zur Situation wichtiger Infektionskrankheiten in Deutschland: Virushepatitis B, C und D im Jahr 2005. Epidemiol Bull 2006;46:399–410.

    Google Scholar 

  2. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004;24:Suppl 1:3–10.

    Article  PubMed  CAS  Google Scholar 

  3. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486–500.

    Article  PubMed  CAS  Google Scholar 

  4. Cornberg M, Protzer U, Dollinger MW, et al. Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV-)infection: upgrade of the guideline, AWMF-Register 021/011. Z Gastroenterol 2007;45:525–74.

    Article  PubMed  CAS  Google Scholar 

  5. Kao JH, Chen PJ, Lai MY. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554–9.

    Article  PubMed  CAS  Google Scholar 

  6. Janssen HL, Zonnefeld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123–9.

    Article  PubMed  CAS  Google Scholar 

  7. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006;101:297–303.

    Article  PubMed  CAS  Google Scholar 

  8. Buster EHCJ, Schalm SW, Janssen HLA. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Best Pract Res Clin Gastroenterol 2008;22:1093–108.

    Article  PubMed  CAS  Google Scholar 

  9. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206–17.

    Article  PubMed  CAS  Google Scholar 

  10. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003;23:81–8.

    Article  PubMed  CAS  Google Scholar 

  11. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006;44:422–31.

    Article  PubMed  CAS  Google Scholar 

  12. Locarnini S, Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antiviral Ther (Lond) 2007;12:Supp l3:15–23.

    Google Scholar 

  13. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 2009;50:227–42.

    Article  PubMed  CAS  Google Scholar 

  14. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041–8.

    Article  PubMed  CAS  Google Scholar 

  15. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748–55.

    Article  PubMed  CAS  Google Scholar 

  16. Ryu SH, Chung YH, Choi MH, et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 2003;39:614–9.

    Article  PubMed  CAS  Google Scholar 

  17. Hui AY, Chan HL, Cheung HY, et al. Systematic review: Treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 2005;22:519–28.

    Article  PubMed  CAS  Google Scholar 

  18. McHutchison JG, Davis G, Esteban-Mur R, et al. Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon alpha-2B alone or in combination with ribavirin. Hepatology 2001;34:244.abstract.

    Google Scholar 

  19. Formann E, Steindl-Munda P, Hofer H, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 2006;23:507–11.

    Article  PubMed  CAS  Google Scholar 

  20. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600–9.

    Article  PubMed  CAS  Google Scholar 

  21. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124–34.

    Article  PubMed  CAS  Google Scholar 

  22. Wagner M von, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522–7.

    Google Scholar 

  23. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004;140:370–81.

    PubMed  CAS  Google Scholar 

  24. McHutchison J, Sulkowski M. Scientific rationale and study design of the Individualized Dosing Efficacy vs Flat Dosing to Assess Optimal Pegylated Interferon Therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2008;15:475–81.

    Article  PubMed  CAS  Google Scholar 

  25. Sulkowski M, Lawitz E, Shiffman ML, et al. Final results of the IDEAL (Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy) phase IIIb study. 43rd Annual Meeting of the European Association for the Study of the Liver (EASL 2008), Milan, April 23–27, 2008.

  26. Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology 2008;48:407–17.

    Article  PubMed  CAS  Google Scholar 

  27. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631–9.

    Article  PubMed  CAS  Google Scholar 

  28. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46:640–8.

    Article  PubMed  CAS  Google Scholar 

  29. Dusheiko GM, Hezode C, Pol S, et al. Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon-alfa-2a with or without ribavirin: further interim analysis results of the PROVE2 study. 43rd Annual Meeting of the European Association for the Study of the Liver (EASL 2008), Milan, April 23–27, 2008.

  30. Roberts S, Cooksley G, Dore G, et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008;48:398–406.

    Article  PubMed  CAS  Google Scholar 

  31. Pockros P, Nelson D, Godofsky E, et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008;48:385–97.

    Article  PubMed  CAS  Google Scholar 

  32. Pockros P, Nelson D, Godofsky E, et al. High relapse rate seen at week 72 for patients treated with R1626 combination therapy. Hepatology 2008;48:1349–50.

    Article  PubMed  Google Scholar 

  33. Lalezari J, Gane E, Rodriguez-Torres M, et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg BID for 28 days. J Hepatol 2008;48:Suppl 2:S29.abstract.

    Article  Google Scholar 

  34. Stauber R, Kessler HH. Drugs in development for hepatitis C. Drugs 2008;68:1347–59.

    Article  PubMed  CAS  Google Scholar 

  35. Manns MP, Foster GR, Rockstroh JK, et al. The way forward in HCV treatment - finding the right path. Nat Rev Drug Discov 2007;6:991–1000.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin, Klinikum Vest GmbH, Behandlungszentrum Paracelsus-Klinik Marl, Marl, Germany

    Markus Reiser

  2. Klinik für Innere Medizin, Klinikum Vest GmbH, Behandlungszentrum Paracelsus-Klinik Marl, Lipper Weg 11, 45770, Marl, Germany

    Markus Reiser

Authors
  1. Markus Reiser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Reiser.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reiser, M. Virushepatitis B und C. Med Klin 104, 356–362 (2009). https://doi.org/10.1007/s00063-009-1074-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00063-009-1074-y

Schlüsselwörter:

Key Words:

Search

Navigation